Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently (Q79954598)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

1 reference

1 reference

Farid NA

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Payne CD

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Small DS

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Winters KJ

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Ernest CS 2nd

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Brandt JT

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Darstein C

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Jakubowski JA

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Salazar DE

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

14 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

27 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

735-741

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17361128%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100139

27 December 2019

exact match

0 references

cites work

Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

Effects of Statins on Platelet Inhibition by a High Loading Dose of Clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021

Cumulative antiplatelet effect of low-dose enteric coated aspirin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100139

7 January 2021